Tech Focus Asia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Focus Asia.

Press releases published on September 2, 2026

Sep. 2, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire

Sep. 2, 2026

Patton and alfanar Partner™ to Accelerate Secure Digital Transformation of Saudi Power Infrastructure

Indeterminate GlobeNewswire

Sep. 2, 2026

BioRestorative Therapies Announces Reverse Stock Split

Indeterminate GlobeNewswire

Sep. 2, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Major Drilling Announces Record Quarterly Revenue for Its First Quarter 2027

Indeterminate GlobeNewswire

Sep. 2, 2026

Zoom Appoints Former Oracle CFO Jeff Epstein to Board of Directors; Jonathan Chadwick to Retire

Indeterminate GlobeNewswire

Sep. 2, 2026

SONORO GOLD ANNOUNCES MANAGEMENT APPOINTMENTS

Indeterminate GlobeNewswire

Sep. 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Byrna Appoints Matt McBrady to Board of Directors

Indeterminate GlobeNewswire

Sep. 2, 2026

Supernus Pharmaceuticals to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Indeterminate GlobeNewswire

Sep. 2, 2026

Shufti Ranks #1 in G2 Fall 2026 Grid® Report for Identity Verification and AML, Earns 40+ Badges Across 12 Categories

Indeterminate EIN Presswire

Sep. 2, 2026

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Indeterminate GlobeNewswire

Sep. 2, 2026

Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH

Indeterminate GlobeNewswire

Sep. 2, 2026

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

nCino to Participate in Upcoming Investor Event 

Indeterminate GlobeNewswire

Sep. 2, 2026

Surrozen to Present at Upcoming Healthcare Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire